NasdaqGS:AMRXPharmaceuticals
Amneal Pharmaceuticals (AMRX) Return To Profit Tests High 60.3x P/E Narrative
Amneal Pharmaceuticals (AMRX) has just posted its FY 2025 numbers, with Q4 revenue of US$814.3 million and basic EPS of US$0.11, capping a trailing twelve month run of US$3.0 billion in revenue and EPS of US$0.23. Over recent quarters the company has seen revenue move from US$702.5 million in Q3 2024 to US$730.5 million in Q4 2024, then to US$695.4 million, US$724.5 million, US$784.5 million and finally US$814.3 million through FY 2025, while quarterly EPS shifted from a loss of US$0.10 to...